Asgard Therapeutics
Asgard Therapeutics AB is pioneering the use of cellular reprogramming in cancer immunotherapy. The scientific founders of Asgard have developed a cellular reprogramming technology that forces cancer cells to present their own antigens to the immune system, triggering expansion of cancer cell-specific killer T cells and cancer elimination. Asgard solution is an off-the-shelf cancer immunotherapy that can be administered to multiple patients inducing a personalized immune response. It can be applied to different cancers, representing a platform technology with vast economic potential.
Asgard Therapeutics
Direct cell reprogramming technologies for cancer immunotherapy.
Founded by Filipe Pereira, Cristiana Pires and Fábio Rosa.
Portfolio company since 2018.
Portfolio Manager LU Holding:
christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78